Subtopic Deep Dive
PDGFRA Mutations GIST
Research Guide
What is PDGFRA Mutations GIST?
PDGFRA mutations in gastrointestinal stromal tumors (GISTs) are activating alterations in the platelet-derived growth factor receptor alpha gene, primarily the D842V mutation, occurring in 5-10% of cases, especially KIT-wildtype gastric GISTs, conferring primary resistance to imatinib.
PDGFRA mutations drive a subset of GISTs independent of KIT signaling, with D842V identified in up to 4% of all GISTs (Corless et al., 2005, 831 citations). These mutations cluster in exons 12, 14, and 18, altering kinase sensitivity to tyrosine kinase inhibitors (Heinrich et al., 2008, 798 citations). KIT-negative GISTs frequently harbor PDGFRA mutations, confirmed in pathologic series of over 1,800 cases (Medeiros et al., 2004, 480 citations).
Why It Matters
PDGFRA D842V mutations identify imatinib-resistant GIST subsets, guiding avapritinib approval for this indication (Casali et al., 2021, 499 citations). Corless et al. (2005) established in vitro insensitivity of PDGFRA mutants to imatinib, shifting therapy to PKC412 or sunitinib for refractory cases (Dêbiec-Rychter et al., 2005, 491 citations). Heinrich et al. (2008) correlated PDGFRA genotypes with sunitinib response in 300+ imatinib-resistant patients, improving progression-free survival. Guidelines integrate PDGFRA genotyping for personalized treatment (Nishida et al., 2015, 464 citations).
Key Research Challenges
Imatinib Resistance Mechanisms
PDGFRA D842V confers primary resistance due to kinase conformational changes, unlike KIT exon 11 mutations responsive to imatinib (Corless et al., 2005). Secondary mutations in PDGFRA exacerbate resistance post-imatinib (Heinrich et al., 2008). Dêbiec-Rychter et al. (2005) showed PKC412 activity against resistant PDGFRA mutants in preclinical models.
KIT-Wildtype GIST Diagnosis
KIT-negative GISTs with PDGFRA mutations mimic smooth muscle tumors, requiring DOG1 IHC and genotyping for confirmation (Medeiros et al., 2004). Up to 4% of GISTs lack KIT expression but harbor PDGFRA alterations. Pathologic reanalysis of 1,869 cases identified PDGFRA-driven subsets (Miettinen et al., 2004).
Novel Inhibitor Development
D842V requires type I inhibitors like avapritinib, unlike type II agents like imatinib (Corless et al., 2005). Sunitinib shows variable activity in PDGFRA-mutant GIST (Heinrich et al., 2008). Guidelines highlight unmet needs for exon 18 inhibitors (Casali et al., 2018).
Essential Papers
Gastrointestinal Stromal Tumors of the Stomach
Markku Miettinen, Leslie H. Sobin, Jerzy Lasota · 2004 · The American Journal of Surgical Pathology · 1.2K citations
Gastrointestinal (GI) stromal tumors (GISTs), the specific KIT- or PDFGRA-signaling driven mesenchymal tumors, are the most common mesenchymal tumors of the GI tract. In this study, we analyzed 186...
<i>PDGFRA</i> Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib
Christopher L. Corless, Arin Schroeder, Diana Griffith et al. · 2005 · Journal of Clinical Oncology · 831 citations
Purpose Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT tyrosine kinase, which is a target for the kinase inhibitor imatinib. A subset of GISTs, however, cont...
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich, Robert G. Maki, Christopher L. Corless et al. · 2008 · Journal of Clinical Oncology · 798 citations
Purpose Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor α (PDGFRA) kinases, which are imatinib targets. Sunitinib, which targets KIT, PDGFR...
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo G. Casali, N. Abecassis, Sebastian Bauer et al. · 2018 · Annals of Oncology · 746 citations
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo G. Casali, Jean‐Yves Blay, N. Abecassis et al. · 2021 · Annals of Oncology · 499 citations
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
Maria Dêbiec‐Rychter, Jan Cools, Herlinde Dumez et al. · 2005 · Gastroenterology · 491 citations
KIT-Negative Gastrointestinal Stromal Tumors
Fabíola Medeiros, Christopher L. Corless, Anette Duensing et al. · 2004 · The American Journal of Surgical Pathology · 480 citations
The diagnosis of gastrointestinal stromal tumor (GIST) is currently based on morphologic features and immunohistochemical demonstration of KIT (CD117). However, some tumors (in our estimation appro...
Reading Guide
Foundational Papers
Start with Corless et al. (2005, 831 citations) for PDGFRA mutation frequency and imatinib sensitivity; Miettinen et al. (2004, 1237 citations) for GIST pathologic context; Medeiros et al. (2004, 480 citations) for KIT-negative diagnostics.
Recent Advances
Casali et al. (2021, 499 citations) and Casali et al. (2018, 746 citations) for updated ESMO guidelines on PDGFRA genotyping and therapy; Nishida et al. (2015, 464 citations) for standardized treatment protocols.
Core Methods
Genotyping via Sanger sequencing or NGS for exons 12/14/18; in vitro kinase assays for inhibitor sensitivity (Corless et al., 2005); genotype-PFS correlation in phase III trials (Heinrich et al., 2008).
How PapersFlow Helps You Research PDGFRA Mutations GIST
Discover & Search
Research Agent uses searchPapers('PDGFRA D842V GIST imatinib resistance') to retrieve Corless et al. (2005, 831 citations), then citationGraph reveals Heinrich et al. (2008) and Dêbiec-Rychter et al. (2005) as high-impact forward citations. exaSearch expands to KIT-wildtype GIST guidelines like Casali et al. (2021). findSimilarPapers on Medeiros et al. (2004) uncovers PDGFRA diagnostics.
Analyze & Verify
Analysis Agent applies readPaperContent to Corless et al. (2005) abstract for D842V frequency (5-13% KIT-wildtype GISTs), then verifyResponse (CoVe) cross-checks mutation spectra against Heinrich et al. (2008). runPythonAnalysis parses genotype-response data from sunitinib trials, computing PFS hazard ratios with pandas. GRADE grading scores Corless et al. (2005) as high evidence for imatinib insensitivity.
Synthesize & Write
Synthesis Agent detects gaps in PDGFRA exon 18 inhibitors via contradiction flagging between Corless et al. (2005) resistance data and Casali et al. (2021) guidelines. Writing Agent uses latexEditText to draft mutation tables, latexSyncCitations for 10-paper bibliographies, and latexCompile for ESMO guideline summaries. exportMermaid generates PDGFRA-KIT signaling pathway diagrams.
Use Cases
"Extract mutation frequencies and survival data from PDGFRA GIST papers for meta-analysis"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of Corless 2005 + Heinrich 2008 data) → CSV export of pooled D842V PFS hazard ratios (researcher gets Excel-ready meta-analysis table).
"Write LaTeX review section on PDGFRA mutations in KIT-wildtype GIST"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Miettinen 2004, Medeiros 2004) + latexCompile → PDF (researcher gets formatted subsection with 5 citations and resistance figure).
"Find code for PDGFRA kinase inhibitor modeling"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis (researcher gets PyTorch script for D842V docking simulations from 2020 preprint repo).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ PDGFRA GIST papers: searchPapers → citationGraph → DeepScan 7-step verification → GRADE-scored report on inhibitor resistance. Theorizer generates hypotheses linking PDGFRA secondary mutations to sunitinib escape (Heinrich 2008 → gap detection → theory diagram). DeepScan analyzes Corless 2005 mutation spectra with CoVe checkpoints for guideline integration (Casali 2021).
Frequently Asked Questions
What defines PDGFRA mutations in GIST?
Activating PDGFRA mutations occur in 5-10% of GISTs, mainly exon 18 D842V in gastric KIT-wildtype tumors, driving imatinib resistance (Corless et al., 2005).
What methods detect PDGFRA mutations?
Next-generation sequencing or PCR-based genotyping identifies exon 12/14/18 mutations; IHC for KIT-negativity prompts PDGFRA testing (Medeiros et al., 2004).
What are key papers on PDGFRA GIST?
Corless et al. (2005, 831 citations) defined mutation spectrum; Heinrich et al. (2008, 798 citations) linked genotypes to sunitinib response; Dêbiec-Rychter et al. (2005, 491 citations) tested PKC412.
What open problems exist?
Optimal inhibitors for PDGFRA D842V beyond avapritinib; secondary resistance mechanisms; prospective trials in rare exon 12/14 mutants (Casali et al., 2021).
Research Gastrointestinal Tumor Research and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching PDGFRA Mutations GIST with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers